HIGHLIGHTS
- who: Michel Siegel et al. from the Basel, Basel, Switzerland have published the research: Validation of a Dendritic Cell and CD4+ T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of Biotherapeutics, in the Journal: Pharmaceutics 2022, 14, x FOR PEER REVIEW of 28/Oct/2022
- what: The aims of this study were to establish an assay threshold to distinguish between positive and negative responses, to determine the optimal cohort size for the assay, and to identify factors affecting assay variability. During the course of the study, healthy donors that had given their blood . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.